SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-011554
Filing Date
2022-06-13
Accepted
2022-06-13 16:10:11
Documents
12
Period of Report
2022-06-09
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fate-20220609.htm   iXBRL 8-K 96065
  Complete submission text file 0000950170-22-011554.txt   212108

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fate-20220609.xsd EX-101.SCH 2519
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fate-20220609_lab.xml EX-101.LAB 12890
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fate-20220609_pre.xml EX-101.PRE 9561
6 EXTRACTED XBRL INSTANCE DOCUMENT fate-20220609_htm.xml XML 4522
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

IRS No.: 651311552 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36076 | Film No.: 221011699
SIC: 2836 Biological Products, (No Diagnostic Substances)